First, CD57 may be used as a marker of prostatic derivation in equivocal cases, such as tumors from the prostatic urethra or bladder neck, or in metastatic cancers of unknown primary (CUP). The gene discussed is B3GAT1; the disease is metastatic malignant neoplasm.